(Reuters) – Johnson & Johnson said on Monday it was slashing the price of its version of the tuberculosis drug bedaquiline to $340 from its original price of $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.
J&J’s bedaquiline, marketed under the brand name Sirturo, will be available at the reduced price to more than 135 eligible countries, through United Nations-hosted Stop TB Partnership’s Global Drug Facility (GDF), created in 2001 to negotiate lower prices for treatments.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
